ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0796

Deciphering Synovial Fluid Immune Dysregulation in Rheumatoid Arthritis through Cytokine Profiling and Single-Cell Transcriptomics
Abstract Number: 0797

Spatial transcriptomics identifies density-sensing fibroblasts in synovial lining
Abstract Number: 0798

Inhibition of Wnt Signaling Attenuates Inflammatory Arthritis Severity
Abstract Number: 0799

Citrullination of neutrophil serine proteases enhances proteolytic activity, stability and autoantigenicity in Rheumatoid Arthritis
Abstract Number: 0800

Microbiota-Derived Indole Promotes Collagen-Induced Arthritis Type-17 Immunity through Intestinal Dendritic Cell Cytokine Production
Abstract Number: 0801

Achieving Sustained Lupus Low Disease Activity State and Remission With Ianalumab (VAY736) in Patients with Systemic Lupus Erythematosus: A post hoc Analysis From a Phase II Study
Abstract Number: 0802

Remission from cutaneous manifestations of lupus with enpatoran, a first-in-class oral small molecule toll-like receptor 7/8 inhibitor: pooled post-hoc exploratory analysis from a randomized placebo-controlled Phase II study
Abstract Number: 0803

Improved Efficacy and Safety Outcomes in Patients with SLE Treated with Belimumab (BEL) Versus Immunosuppressants (IS), in Addition to Antimalarials (AM) and Glucocorticoids (GC): A Post Hoc Summary of Five Phase 3 Trials
Abstract Number: 0804

Comparative Risk of All-Cause Mortality with Belimumab versus Oral Immunosuppressant Use in Patients with Non-Renal Systemic Lupus Erythematosus
Abstract Number: 0805

Safety and Efficacy of Hydroxychloroquine According to Weight-based Dose: Results of a Global Systematic Review and Meta-analysis
Abstract Number: 0806

Comparative Risk of Infection-Related Complications in Systemic Lupus Erythematosus Patients Treated with Anifrolumab versus Belimumab: A Target Trial Emulation
Abstract Number: 0807

Deciphering Synovitis in Systemic Sclerosis
Abstract Number: 0808

Spatial Transcriptomics Show Fibroblast LIF Receptor Drives Fibrosis in Systemic Sclerosis
Abstract Number: 0809

Human blood vessel organoids as a model of vasculopathy in systemic sclerosis
Abstract Number: 0810

Spatial Transcriptomic-based Phenotyping of the Fibroblast Niches in Systemic Sclerosis-associated Primary Heart Involvement

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].